Ewelina Lukaszyk
Overview
Explore the profile of Ewelina Lukaszyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
113
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lukaszyk E, Bien-Barkowska K, Bien B
Nutrients
. 2021 Apr;
13(4).
PMID: 33801694
Identifying factors that affect mortality requires a robust statistical approach. This study's objective is to assess an optimal set of variables that are independently associated with the mortality risk of...
2.
Lukaszyk E, Bien-Barkowska K, Bien B
Nutrients
. 2018 Aug;
10(8).
PMID: 30115862
The study objective is to investigate whether vitamin D is associated with the cognitive function of geriatric patients. This cross-sectional study involved 357 patients hospitalized in the geriatric ward who...
3.
Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J
Int Urol Nephrol
. 2017 Nov;
50(1):121-125.
PMID: 29134616
Background/aims: Zonulin is the only known regulator of intestinal permeability. It is also considered as a potential inflammatory marker in several conditions such as diabetes and inflammatory bowel syndrome. The...
4.
Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J
Arch Med Sci
. 2017 Jul;
13(4):845-850.
PMID: 28721153
Introduction: Fibroblast growth factor 23 (FGF-23) levels are elevated in impaired renal function. Inflammation and iron are potential regulators of FGF-23. The aim of the study was to evaluate the...
5.
Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J
Int Urol Nephrol
. 2016 Apr;
48(6):839-44.
PMID: 27043030
Purpose: The aim of the study was to assess GDF-15 and iron status in patients in early stages of chronic kidney disease with a particular emphasis on elderly population in...
6.
Lukaszyk E, Malyszko J
Adv Med Sci
. 2015 Aug;
60(2):335-41.
PMID: 26233637
Copeptin, a C-terminal part of the precursor pre-provasopressin is a novel biomarker of arginine-vasopressin (AVP) system. Measurements of AVP concentration are not used in clinical practice because of technical difficulties....
7.
Malyszko J, Lukaszyk E, Glowinska I, Durlik M
Sci Rep
. 2015 Jul;
5:11684.
PMID: 26175216
Renal transplantation ensures distinct advantages for patients with end-stage kidney disease. However, in some cases early complications can lead to allograft dysfunction and consequently graft loss. One of the most...
8.
Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Tobolczyk J, Bodzenta-Lukaszyk A, Malyszko J
Kidney Blood Press Res
. 2015 Jul;
40(4):366-73.
PMID: 26160488
Background/aims: One of the most common causes of anemia of chronic disease (ACD) is chronic kidney disease. The main pathomechanism responsible for ACD is subclinical inflammation. The key element involved...
9.
Lukaszyk E, Malyszko J
Przegl Lek
. 2014 Jul;
71(2):95-7.
PMID: 25016784
Subclinical inflammation is one of the key mechanisms responsible for the development and progression of chronic kidney disease. It may stem from uremia, ongoing inflammation in kidney as well as...